Biolinerx Ltd

Northwest Biotherapeutics is a biotechnology company that focuses on the clinical development of autologous immunotherapy products for cancer. The company s technology platform, DCVax, uses a patient s own dendritic cells. These cells are the starter engines of the immune system, which are loaded with tumor proteins or antigens. Injection of dendritic cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The company s two lead product candidates, DCVax-Prostate and DCVax-Brain, are in Food & Drug Administration-allowed late stage clinical trials, from which licensure is possible. Related products in the company s pipeline are also ready to enter Phase I clinical trials. Northwest Biotherapeutics is located in Bothell, Wash.

Rise Therapeutics LLC, located in Rockville, MD, is dedicated to advancing innovative immunotherapies aimed at transforming patient care. The organization actively seeks strategic partnerships with academic and industry leaders within the biotech and pharmaceutical sectors. With a focus on groundbreaking therapeutic solutions, Rise Therapeutics leverages its scientific capabilities and pipeline to address unmet medical needs. The company is committed to fostering collaboration to enhance healthcare outcomes for patients globally. Generated from the website

GlycoMimetics develops novel small molecule therapeutics based upon the roles that carbohydrates play in biological processes. The company believes that carbohydrate mimics, or glycomimetic compounds, represent a new class of drugs. It has identified some compounds with potential therapeutic utility. One class has potential in the treatment of infectious diseases with a novel mechanism of action; the second is a class of anti-inflammatory compounds that have been shown to reduce key measures of inflammation. One of GMI s lead opportunities is to treat or prevent infections caused by Pseudomonas aeruginosa. Its objective in this program is to develop a drug that would be used in conjunction with antibiotics against chronic infections that have failed to respond to antibiotic treatment. The company also has compounds that inhibit selectin binding. Its initial focus in this program is to develop a product to treat acute exacerbations of asthma and chronic obstructive pulmonary disease. GlycoMimetics is headquartered in Gaithersburg, Md.